ALG-000111 / Aligos Therap - LARVOL DELTA

[VIRTUAL] Capsid assembly modulator ALG-000111 and its prodrug ALG-000286 display excellent in vitro and in vivo antiviral activity (EASL-ILC 2021) - "With sub-nanomolar activity and deep knockdown of HBV DNA in cell-based assays and the AAV-HBV mouse model, ALG- 000286 is a promising Class II CAM candidate for further development."

Preclinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021 (GlobeNewswire) - "Five scientific posters to be presented at upcoming EASL ILC meeting; All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clinical development in H2 2021 and H1 2022, respectively; Antiviral activity data from at least one cohort of CHB patients for ALG-010133 and ALG-000184 expected to be presented in H2 2021....We expect to present preliminary data from these Phase 1b studies in H2 2021. Once Phase 1b studies are completed, we plan to advance these drug candidates into Phase 2 studies in H2 2022...and are on track to start Phase 1 trials in H2 2021, and H1 2022, respectively."

New P1 trial • New P2 trial • P1 data • Preclinical • Hepatitis B • Infectious Disease

Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021 (GlobeNewswire) - P1, N=164; NCT04485663; Sponsor: Aligos Therapeutics; "First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients; Presentations include nonclinical data from 3 other CHB programs...ALG-010133 was generally safe and well tolerated in HVs when given as single and multiple (3 weekly) subcutaneous doses of up to 200 and 180 mg, respectively...In vitro, ALG-000111 demonstrated sub-nanomolar potency, sustained antiviral activity and significant HBV DNA knockdown. The compound’s prodrug form, ALG-000286, showed strong in vivo antiviral activity in an AAV-HBV mouse model as measured by declines in HBV DNA...Aligos’ siRNA candidate ALG-125755 and of Aligos’ ASO candidate ALG-020572 were evaluated for any additive or synergistic effects with respect to S-antigen knockdown, both in vitro and in vivo."

P1 data • Preclinical • Hepatitis B • Infectious Disease